Xu Binghe相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌：随机3期PHILA试验的长期生存结果

期刊:Bmj-British Medical Journal

影响因子:42.7

doi:10.1136/bmj-2025-087259

Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe

发表日期：2026

文献求助收藏

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial

比瑞西尼联合氟维司群治疗内分泌进展后的晚期乳腺癌：BRIGHT-2 III期随机临床试验

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2026.0318

Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Hu, Yan; Wang, Qiuli; Duan, Xianghui; Yang, Fan; Wang, Li; Xu, Binghe

发表日期：2026

文献求助收藏

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

阿福塞替尼联合氟维司群治疗既往接受过治疗的HR阳性、HER2阴性晚期乳腺癌：一项Ib期试验

期刊:Nature Communications

影响因子:15.7

doi:10.1038/s41467-026-69225-2

Zhang, Pin; Sun, Tao; Wang, Ying; Li, Wei; Tong, Zhongsheng; Phadke, Sneha; Feinstein, Trevor; Ma, Wenyue; Guo, Pengfei; Zhang, Minhua; Yue, Yong; Xu, Binghe

发表日期：2026

文献求助收藏

Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients

红细胞通过凋亡小体内化细胞外DNA，这对癌症患者具有临床意义

期刊:Advanced Science

影响因子:14.1

doi:10.1002/advs.202511408

Zeng, Zihang; Yi, Zongbi; Hu, Jing; Li, Jiali; Xu, Yu; Guo, Xiuli; Ji, Qian; Feng, Kaixiang; Zhang, Ying; Bai, Sirui; Tan, Yushuang; Yan, Yufei; Han, Linzhi; Jiang, Jing; Wang, Tengfei; Wang, Xiang; Zhan, Ziqing; Huang, Ruiying; Zhang, Jinfang; Xie, Conghua; Xu, Binghe

细胞生物学

发表日期：2026

文献求助收藏

Extracellular matrix-derived mechanical force induces CDK4/6 inhibitor resistance by inhibiting NEK10 dependent cell cycle regulation in breast cancer

细胞外基质衍生的机械力通过抑制NEK10依赖的细胞周期调控，诱导乳腺癌细胞产生CDK4/6抑制剂耐药性。

期刊:International Journal of Surgery

影响因子:10.1

doi:10.1097/JS9.0000000000004527

Li, Cong; Wang, Jian; Jin, Yuming; Huang, Yumeng; Hong, Ruoxi; Chen, Dongshao; Lin, Shaoyan; Chen, Limin; Wu, Huailiang; Du, Ting; Xu, Binghe; Wang, Wan; Wang, Shusen

细胞生物学

发表日期：2026

文献求助收藏

Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study

腹泻与接受吡咯替尼治疗的 HER2 阳性晚期乳腺癌患者生存率之间的关联：来自真实世界 PRETTY 研究的里程碑式分析

影响因子:7.9

doi:10.1016/j.breast.2026.104783

Li, Yiqun; Wang, Wenna; Tong, Zhongsheng; Wu, Xinhong; Cai, Li; Ouyang, Quchang; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Xu, Binghe

发表日期：2026

文献求助收藏

Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study

Ki-67 指数在乳腺恶性叶状肿瘤中的预后价值：一项多中心真实世界研究

期刊:Breast Cancer Research

影响因子:5.6

doi:10.1186/s13058-026-02238-3

Zhou, Yiran; Guo, Changyuan; Wang, Yan; Xu, Hangcheng; Sa, Qiang; Che, Shunan; Chen, Shanshan; Lan, Bo; Luo, Yang; Wang, Jiani; Mo, Hongnan; Cai, Ruigang; Li, Qiao; Fan, Ying; Zhang, Pin; Ma, Fei; Xu, Binghe; Wang, Jiayu

发表日期：2026

文献求助收藏

Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer

CDK4/6抑制剂新辅助内分泌治疗在局部晚期乳腺癌中的疗效

期刊:Oncologist

影响因子:4.2

doi:10.1093/oncolo/oyag032

Zhang, Mengqi; Li, Mingxiao; Zhou, Shihan; Jiang, Mingxia; Liu, Jiaxuan; Yang, Xue; Qin, Ling; Abudureheiyimu, Nilupai; Shi, Xiuqing; Li, Lixi; Li, Fengjuan; Guan, Xiuwen; Ma, Fei; Xu, Binghe; Li, Qiao

发表日期：2026

文献求助收藏

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study

PARP抑制剂治疗携带同源重组修复通路基因突变的转移性乳腺癌患者的疗效和安全性：一项回顾性多中心真实世界研究

期刊:Therapeutic Advances in Medical Oncology

影响因子:4.2

doi:10.1177/17588359251411096

Peng, Xuenan; Song, Ruixia; Fan, Ying; Wang, Jiayu; Li, Qiao; Mo, Hongnan; Wang, Jiani; Luo, Yang; Chen, Shanshan; Sun, Xiaoying; Zhang, Jintao; Zhang, Pin; Xu, Binghe; Lan, Bo; Ma, Fei

发表日期：2026

文献求助收藏

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

达托泊单抗德鲁替康对比化疗治疗既往接受过治疗的不可手术/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌：TROPION-Breast01研究的主要结果

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.24.00920

Bardia, Aditya; Jhaveri, Komal; Im, Seock-Ah; Pernas, Sonia; De Laurentiis, Michelino; Wang, Shusen; Martínez Jañez, Noelia; Borges, Giuliano; Cescon, David W; Hattori, Masaya; Lu, Yen-Shen; Hamilton, Erika; Zhang, Qingyuan; Tsurutani, Junji; Kalinsky, Kevin; Rubini Liedke, Pedro Emanuel; Xu, Lu; Fairhurst, Rick M; Khan, Sabrina; Denduluri, Neelima; Rugo, Hope S; Xu, Binghe; Pistilli, Barbara

免疫/内分泌

发表日期：2025

文献求助收藏